Quintiles And Eisai Collaborate To Develop Cancer Compounds
This article was originally published in PharmAsia News
Executive Summary
Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30